KRAS and non-small cell lung carcinoma: In order to preclinically assess the in vivo efficacy of BET inhibition by BAY 1238097 in an immunocompetent context, we made use of two well-characterized KRAS-driven genetically engineered mouse models of PDAC (LSL-KrasG12D;Pdx1-Cre;p53ER/ER) and NSCLC (LSL-KrasG12D;p53ER/ER) [23, 24].